Peter Moosmann

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2007-01-25
Last Posted Date
2015-04-03
Lead Sponsor
Peter Moosmann
Target Recruit Count
12
Registration Number
NCT00426855
© Copyright 2024. All Rights Reserved by MedPath